Listen
TEKTROTYD (99mTc-EDDA/HYNIC-TOC), radiopharmaceutical for diagnostic use
DIAGNOSIS - New medicinal product
Opinions on drugs -
Posted on
Nov 15 2017
Reason for request
Inclusion
No clinical benefit demonstrated in the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.
- TEKTROTYD has Marketing Authorisation in the diagnosis of neuroendocrine tumours.
- It is intended for single-photon emission computed tomography or planar scintigraphy and binds specifically to somatostatin receptors.
- Studies have not demonstrated any benefit in relation to its clinically relevant comparators.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
